Intensive care management of phenytoin intoxication in a patient with iatrogenic overdose combined with glycol - Mercan A, Karabiyik L.
BACKGROUND: Phenytoin is a commonly prescribed antiepileptic drug. The narrow therapeutic index, the wide individual variability in the rate of Phenytoin metabolism and clearance are responsible from the observed dose-related toxicity. Parenteral form of P... (Source: SafetyLit)
Source: SafetyLit - February 27, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Phenytoin-induced Dyskinesia Phenytoin-induced Dyskinesia
Several antiepileptic drugs have been linked to involuntary movements. This case highlights the need to be aware of phenytoin-induced dyskinesia, which is reversible upon discontinuation of the drug.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
A retrospective case series on valproic acid for early post-traumatic seizure prophylaxis after traumatic brain injury in patients with concomitant agitation - Nicole Gilliam D, Sarangarm P, Elwood K.
PURPOSE: Early post-traumatic seizures occur within 7 days following a traumatic brain injury and may lead to additional brain damage and poor outcomes. Levetiracetam or phenytoin is often used for seizure prophylaxis in this patient population, but valpro... (Source: SafetyLit)
Source: SafetyLit - September 19, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Phenytoin toxicity with high dose, concomitant ascorbic acid dosing - Schuh MJ, Mustain K, Crosby S.
High dose ascorbic acid may increase risk of phenytoin toxicity. This case report demonstrates high phenytoin levels resulting in adverse drug reactions subsequent to dosing concomitantly with high dose vitamin C, or ascorbic acid (AA), as a precaution aga... (Source: SafetyLit)
Source: SafetyLit - June 17, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first ...
Source: Johnson and Johnson - March 30, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
TITUSVILLE, N.J., March 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label update for CABENUVA (cabotegravir and rilpivirine), giving healthcare professionals and people living with human immunodeficiency virus (HIV-1) in the U.S. the option to start this once-monthly or every-two-month injectable treatment without the need for the oral lead-in phase (daily cabotegravir and rilpivirine tablets, taken for one month prior to initiation of cabotegravir and rilpivirine injections).1 Clinical data demonstrated the regimen di...
Source: Johnson and Johnson - March 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both monthly dosing an...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a stable regimen,...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Seizure in the Skies of Remoteness: A Case Review
Conclusion
While this case review describes an unusual approach to a medical retrieval, remote health care providers in developing nations face major clinical, ethical and legal challenges such as these described. The challenges of prehospital care are dynamic, yet in the remote context they are even more so. In these situations, a careful assessment of risk verses reward is paramount. In these situations, it I just as important to withhold certain interventions as it is to administer them.
References
Broughton W. Pre-hospital paediatric seizures: midazolam versus diazepam. Journal of Paramedic Practice. 2014;6(10...
Source: JEMS: Journal of Emergency Medical Services News - December 15, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Patient Care Air Ambulance Case Report EMS Paramedic Source Type: news
Seizure in the Skies of Remoteness: A Case Review
Conclusion
While this case review describes an unusual approach to a medical retrieval, remote healthcare providers in developing nations face major clinical, ethical and legal challenges such as these described. The challenges of prehospital care are dynamic, yet in the remote context they are even more so. In these situations, a careful assessment of risk verses reward is paramount. In these situations, it I just as important to withhold certain interventions as it is to administer them.
References
Broughton W. Pre-hospital paediatric seizures: midazolam versus diazepam. Journal of Paramedic Practice. 2014;6(10)...
Source: JEMS Latest News - December 15, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Patient Care Air Ambulance Case Report EMS Paramedic Source Type: news
Seizure in the Skies of Remoteness: A Case Review
Conclusion
While this case review describes an unusual approach to a medical retrieval, remote health care providers in developing nations face major clinical, ethical and legal challenges such as these described. The challenges of prehospital care are dynamic, yet in the remote context they are even more so. In these situations, a careful assessment of risk verses reward is paramount. In these situations, it I just as important to withhold certain interventions as it is to administer them.
References
Broughton W. Pre-hospital paediatric seizures: midazolam versus diazepam. Journal of Paramedic Practice. 2014;6(10...
Source: JEMS Patient Care - December 15, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Patient Care Air Ambulance Case Report EMS Paramedic Source Type: news
Seizure in the Skies of Remoteness: A Case Review
Conclusion
While this case review describes an unusual approach to a medical retrieval, remote health care providers in developing nations face major clinical, ethical and legal challenges such as these described. The challenges of prehospital care are dynamic, yet in the remote context they are even more so. In these situations, a careful assessment of risk verses reward is paramount. In these situations, it I just as important to withhold certain interventions as it is to administer them.
References
Broughton W. Pre-hospital paediatric seizures: midazolam versus diazepam. Journal of Paramedic Practice. 2014;6(10...
Source: JEMS Operations - December 15, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Patient Care Air Ambulance Case Report EMS Paramedic Source Type: news
